Reneo Pharmaceuticals
OnKure is committed to discovering and developing the next generation of oncology precision medicines targeting biologically validated drivers of cancer that are underserved by current therapies. Using a structure-based drug design platform, they aim to build a robust pipeline of drug candidates with optimal tolerability and efficacy, focusing on targeted therapies such as the selective PI3KαH1047R inhibitor OKI-219. Their mission is to become a leader in targeting oncogenic PI3Kα and advancing precision medicine for cancer patients.
Industries
Nr. of Employees
medium (51-250)
Reneo Pharmaceuticals
6707 Winchester Circle, Suite 400, Boulder, Colorado 80301
Products
Clinical-stage mutant-selective PI3Kα H1047R inhibitor (lead program)
A small-molecule candidate designed to selectively inhibit the PI3Kα H1047R oncogenic mutant; advanced to IND clearance and Phase 1 initiation.
Clinical-stage Class 1 HDAC inhibitor (first-in-human candidate)
A class-selective histone deacetylase inhibitor advanced into first-in-human trials to evaluate safety, tolerability and dosing in advanced solid tumors.
Clinical-stage mutant-selective PI3Kα H1047R inhibitor (lead program)
A small-molecule candidate designed to selectively inhibit the PI3Kα H1047R oncogenic mutant; advanced to IND clearance and Phase 1 initiation.
Clinical-stage Class 1 HDAC inhibitor (first-in-human candidate)
A class-selective histone deacetylase inhibitor advanced into first-in-human trials to evaluate safety, tolerability and dosing in advanced solid tumors.
Services
Partnerships with academic cancer centers and clinical sites to design and execute first-in-human and early phase oncology trials.
End-to-end small-molecule discovery capabilities including computational design, medicinal chemistry, in vitro and in vivo pharmacology, and IND-enabling studies.
Formulation design, process modeling and scale-up activities to support clinical supply, including enabled formulation technologies.
Regulatory planning, IND preparation and global regulatory strategy to support clinical development and approvals.
Partnerships with academic cancer centers and clinical sites to design and execute first-in-human and early phase oncology trials.
End-to-end small-molecule discovery capabilities including computational design, medicinal chemistry, in vitro and in vivo pharmacology, and IND-enabling studies.
Formulation design, process modeling and scale-up activities to support clinical supply, including enabled formulation technologies.
Regulatory planning, IND preparation and global regulatory strategy to support clinical development and approvals.
Expertise Areas
- Structure-based drug design
- Computational drug discovery
- Medicinal chemistry and discovery chemistry
- DMPK and clinical pharmacology
Key Technologies
- Structure-based and ligand-based design
- Virtual screening and molecular modeling
- Computational chemistry and docking
- Medicinal chemistry and SAR optimization